New eye drops could heal stubborn corneal wounds in weeks

NCT ID NCT07519902

First seen May 05, 2026 · Last updated May 13, 2026 · Updated 1 time

Summary

This study tests an eye drop containing a human nerve growth factor (cenegermin) to see if it can heal persistent corneal epithelial defects (PCED) — stubborn wounds on the eye's surface that won't close with standard treatments. About 150 adults with PCED for at least 14 days will receive either the active drop or a placebo for up to 8 weeks, with follow-up for 40 weeks. The main goal is complete healing of the cornea by week 4, maintained through week 8.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERSISTENT CORNEAL EPITHELIAL DEFECT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

Locations

  • Houston Eye Associates (HEA)

    Houston, Texas, 77030, United States

  • Midwest Vision Research Foundation

    Chesterfield, Missouri, 63017, United States

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114, United States

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

Conditions

Explore the condition pages connected to this study.